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Summary
BACKGROUND: Several studies found that patients with
atrial fibrillation (AF) have an increased risk of cognitive
decline and dementia over time. However, the magnitude
of the problem, associated risk factors and underlying
mechanisms remain unclear.
METHODS: This article describes the design and method-
ology of the Swiss Atrial Fibrillation (Swiss-AF) Cohort
Study, a prospective multicentre national cohort study of
2400 patients across 13 sites in Switzerland. Eligible pa-
tients must have documented AF. Main exclusion criteria
are the inability to provide informed consent and the pres-
ence of exclusively short episodes of reversible forms
of AF. All patients undergo extensive phenotyping and
genotyping, including repeated assessment of cognitive
functions, quality of life, disability, electrocardiography and
cerebral magnetic resonance imaging. We also collect in-
formation on health related costs, and we assemble a
large biobank. Key clinical outcomes in Swiss-AF are
death, stroke, systemic embolism, bleeding, hospitalisa-
tion for heart failure and myocardial infarction. Information
on outcomes and updates on other characteristics are be-
ing collected during yearly follow-up visits.
RESULTS: Up to 7 April 2017, we have enrolled 2133 pa-
tients into Swiss-AF. With the current recruitment rate of
15 to 20 patients per week, we expect that the target sam-
ple size of 2400 patients will be reached by summer 2017.
CONCLUSION: Swiss-AF is a large national prospective
cohort of patients with AF in Switzerland. This study will
provide important new information on structural and func-
tional brain damage in patients with AF and on other AF
related complications, using a large variety of genetic,
phenotypic and health economic parameters.
Swiss-AF study investiga-
tors are listed in appendix 1
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Introduction
Atrial fibrillation (AF) is the most common cardiac ar-
rhythmia in the general population [1, 2]. As a result of the
ongoing ageing of our population and other factors, the in-
cidence of AF is expected to further increase in the near
future [3]. Compared with individuals without AF, AF pa-
tients have an increased risk of serious complications, in-
cluding death, stroke and congestive heart failure [4–7].
Cognitive dysfunction and dementia put an enormous so-
cioeconomic burden on public health for ageing societies
[8]. Recent evidence suggests an increased risk of demen-
tia among AF patients [9–12]. For example, the relative
risk (95% confidence interval) of cognitive impairment
in a meta-analysis of 21 individual studies was 1.34
(1.13–1.58) in individuals with AF without a prior stroke,
and 2.70 (1.82–4.00) in those with a prior stroke [11].
These data suggest that a prior stroke substantially increas-
es the risk of cognitive impairment in AF patients. Howev-
er, these studies also showed that this relationship is partly
independent of clinically overt strokes, but the underlying
mechanisms are currently unknown.
Cerebral magnetic resonance imaging (cMRI) provides de-
tailed information on brain structure and function. The oc-
currence of silent cerebral infarctions (SCI), which have
been found in up to 11% of individuals from the general
population [13], could be mechanistically involved in the
occurrence of cognitive impairment among AF patients
(fig. 1). Cerebral microbleeds (fig. 2) are another structural
correlate that potentially explain the link between AF and
cognitive dysfunction [14], as some studies found a higher
prevalence of microbleeds in patients with stroke or tran-
sient ischaemic attack (TIA) and a history of AF [15]. Oth-
er factors such as progression of the arrhythmia, concomi-
tant diseases or medical treatments may also contribute to
the cognitive decline in AF patients.
However, large systematic investigations on the relation-
ship of cMRI parameters and cognitive decline in AF pa-
tients are currently unavailable. Therefore, one of the key
aims of this large prospective cohort study is to assess the
Figure 2: Cerebral microbleeds.Cerebral microbleeds (arrows)
cause susceptibility related signal loss and hence appear dark on
susceptibility weighted imaging (SWI).
Figure 1: Small ischaemic stroke.A small subacute ischaemic stroke is depicted on fluid attenuated inversion recovery (FLAIR, left, arrow).
The lesion shows signs of restricted diffusion and is hyperintense on diffusion weighted imaging (DWI, right, arrow)
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interrelationships between structural alterations on cMRI
and cognitive decline among patients with established AF,
in order to improve our knowledge on this crucial public
health problems. This research platform will also allow us
to assess differences in cognitive function and brain lesions
on cMRI among patients with different AF types. In this
publication, we describe the detailed methodology of the
Swiss Atrial Fibrillation (Swiss-AF) cohort study.
Methods
Swiss-AF is a prospective multicentre observational cohort
study across 13 centres in Switzerland. Eligible patients
must be ≥65 years old and have either paroxysmal AF
defined as: self-terminating AF lasting <7 days that does
not require cardioversion [16] and that was documented at
least twice within the last 60 months; persistent AF defined
as AF sustained ≥7 days and/or requiring cardioversion,
documented within the last 60 months by ECG or rhythm
monitoring devices; or permanent AF (cardioversion has
failed or not been attempted). The most current guidelines
at the time of protocol preparation were used for Swiss-AF.
In order to assess the socioeconomic aspects of AF in in-
dividuals who are potentially part of the active workforce,
we aim to enrol 300 participants aged 45–65 years into the
study. Main exclusion criteria for Swiss AF are the inabili-
ty to provide informed consent, the presence of exclusive-
ly nonsustained episodes of secondary forms of AF (e.g.,
after cardiac surgery or severe sepsis) or any acute illness
within the last 4 weeks. The latter group of patients is eligi-
ble for enrolment after stabilisation of their acute episode.
Eligible candidates for enrolment in Swiss-AF were ob-
tained by comprehensive screening of in- and outpatients
in participating hospitals and by contacting general practi-
tioners in the area. The study protocol has been approved
by the local ethics committees, and informed written con-
sent is obtained from each participant.
An overview of the study procedures is provided in table
1. The study case report forms have been previously vali-
dated and collect detailed information on personal charac-
teristics, risk factors, co-morbidities, current medications,
physical activity, nutrition and medication adherence. De-
tailed information on medical resource use is obtained.
All data are collected in a standardized manner by trained
study personnel. De-identified data are entered in a web-
based database hosted by the Clinical Trial Unit in Basel.
Clinical measures
Body weight is obtained from each participant in light
clothing and without shoes using a calibrated device. Body
height is measured without shoes using a calibrated device.
Heart rate is obtained by pulse palpation for at least 30 sec-
onds. Blood pressure is measured in a supine position af-
ter at least 5 minutes of rest using a validated oscillometric
device. Three consecutive measures are obtained, and the
mean of the last two will be used for most analyses.
Resting electrocardiogram
Resting 16-lead ECG recordings of 5 minutes duration are
obtained in all participants using the same ECG acquisition
technology at all centres (CS-200 Excellence and CS-200
Touch, Schiller AG, Baar, Switzerland). The digital ECGs
are stored with a sampling frequency of 1 kHz (signal
bandwidth 0.04–387 Hz) and a resolution of 1 µV/bit. The
sampling frequency is twice as high as that of standard
ECG devices and will allow advanced signal processing
analyses focusing on P-wave markers during sinus rhythm
(morphology and variability) as well as fibrillatory mark-
ers during AF (AF amplitudes and rate, entropy, RR vari-
ability). All de-identified ECG recordings are being stored
in a central ECG core laboratory at the Cardiocentro in
Lugano.
Blood sampling
Non-fasting venous blood samples are collected from each
patient at baseline and at 2 years of follow-up, following
written standard operating procedures. Serum, plasma,
whole blood and gene expression samples are obtained,
processed immediately, centrifuged if necessary and
aliquoted into cryotubes to be stored at ˗80°C in a cen-
tralised biobank at the University Hospital Basel. All en-
rolled participants are currently undergoing genotyping us-
ing the HumanCoreExome-12 BeadChip platform. More
advanced genetic analyses will be planned in the future.
Cerebral magnetic resonance imaging
A standardised cMRI-protocol that does not need applica-
tion of contrast agents has been implemented in all par-
ticipating centres and is shown in table 2. The cMRI core
protocol has been installed on an MR scanner at each par-
ticipating site, at either 1.5 or 3 Tesla. Individual patients
are investigated on the same scanner with identical se-
quence protocol at baseline and after 2 years whenever
possible.
Table 1: Overview of study procedures.
Procedure Baseline Year 1 Year 2 Year 3 Year
4+*
Written informed con-
sent
X
Study case report
form
X X X X (X)
Clinical measures X X X X (X)
Resting electrocar-
diogram
X X X X (X)
Outcomes X X X (X)
Cerebral MRI X X
Cognitive assess-
ment
X X X X (X)
Blood sampling X X
Disability, quality of
life
X X X X (X)
Health economics X X X X (X)
MRI = magnetic resonance imaging * Long term perspective, no fund-
ing obtained yet
Table 2: Cerebral magnetic resonance imaging protocol.
MRI sequence Orientation Slice thick-
ness
Fluid Attenuated Inversion Recovery
(FLAIR)
axial 3 mm
Diffusion weighted imaging (EPI) axial 3 mm
Susceptibility weighted imaging
(SWI, T2*)
axial 3 mm
High-resolution 3D-T1w MP-RAGE sagittal 1 mm
(isotropic)
Time of flight MR-angiography (ToF) axial 0.8 mm
MRI = magnetic resonance imaging
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Data are being checked and evaluated first on site and then
transferred to the Medical Image Analysis Centre (MIAC
AG) Basel, which serves as the central neuroimaging core
lab. MIAC has set up an interne-tbased data transfer (web-
portal) in order to receive, check and accept cMRI stud-
ies from the participating sites, as well as to communicate
with them. Participating sites had to perform a dummy test
scan with all required sequences, including a repositioning
scan for control purposes. Only after the test scan had been
accepted by the MIAC, could sites proceed with the inclu-
sion of patients. De-identified images are transferred elec-
tronically. MIAC provides quality assessment forms for all
studies. All images are analysed by trained MRI techni-
cians and validated by board-certified radiologists accord-
ing to a prespecified analysis plan. Lesions are evaluat-
ed using the AMIRA software which calculates volumes
and number of lesions. Atrophy measurements are calcu-
lated by means of SIENA X (normalised brain volume)
and SIENA [17, 18].
Cognitive assessments
Study personnel have been trained centrally to perform a
standardized neurocognitive assessment. A series of instru-
ments has been selected based on literature review and dis-
cussion with experts, and are shown in table 3.
The Montreal Cognitive Assessment evaluates visuospatial
and executive functions, confrontation naming, memory,
attention, language and abstraction [19]. Patients can ob-
tain a maximum of 30 points and a score of <26 usually in-
dicates cognitive impairment. The Trail Making Test, parts
A and B increase the depth of assessment with respect to
psychomotor speed and executive functions [20]. This se-
ries of instruments has been successfully used previously
in large multicentre studies [24]. In addition, animal flu-
ency for 1 minute [21] will assess semantic fluency – a
combination of semantic memory and executive functions,
which complements phonemic fluency within the Montre-
al Cognitive Assessment. The Digit Symbol Substitution
Test (DSST) is a subtest of the Wechsler Adult Intelligence
Scale [22]. The DSST assesses aspects of cognition such
as information processing speed, visuomotor coordination
and attention. Scores on the DSST range from zero (worst)
to 90 (best). Depressive symptoms are assessed using the
Geriatric Depression Scale, where a score of five or more
points indicates depression [23].
Quality of life and disability
The European Quality of life-5 Dimensions questionnaire
(EQ-5D) is a widely used, non-disease specific preference-
based instrument to measure health related quality of life,
and is used for this purpose in the current study [25].
In combination with published valuation algorithms, the
EQ-5D provides a basis for the calculation of utilities, i.e.,
Table 3: Instruments for cognitive assessment.
Instrument name Time requirement
Montreal Cognitive Assessment
[19]
10 minutes
Trail Making Test (parts A and B)
[20]
8 minutes
Semantic Fluency, animals [21] 2 minutes
Digit Symbol Substitution Test [22] 3 minutes
Geriatric Depression Scale, 15
items [23]
5 minutes
quality of life weights suitable to inform health economic
evaluation studies. Disability is assessed using the Barthel
Index [26].
AF-related medical resource use and costs
Health insurance claims data collected over the entire
study period complement basic medical resource use in-
formation covered by the case report form for all patients,
and will be used to evaluate medical resource use and med-
ical costs. Collection of claims data is restricted to pa-
tients enrolled with four large health insurance companies
and covers 40–50% of the study population. These compa-
nies were selected because of their interest in making data
available for research, and because they are able to provide
their data in a consistent format. One challenge that aris-
es when Swiss claims data are used is to distinguish AF-
related from non-AF-related use of medical resources. For
inpatient episodes, Diagnosis-Related Group (DRG) codes
will provide a basis for distinction. Given lack of Interna-
tional Classification of Diseases (ICD)-10 diagnosis codes
on outpatient claims, outpatient services will be classified
using the “Tessiner Code” (www.marcmuret.ch/tessiner-
code0.htm), and to-be-developed algorithms informed by
drugs prescribed, services performed, and clinical events
recorded in the Swiss-AF case report forms.
In addition, patient diaries are used to collect information
on medical resource use outside the treating study centre in
a subsample of 218 patients (13.7%), for whom health in-
surance claims data are also collected. The main purpose is
to achieve a cross-validation of the claims data, to support
the distinction of AF-related from non-AF-related resource
use.
Finally, among patients aged <65 years at enrolment, a
study-specific questionnaire is administered to assess days
off work due to AF and potentially related conditions,
changes in the actual and desired degree of employment,
and early retirement, as a basis for estimating indirect costs
of AF and hence the societal impact of the disease (appen-
dix 2, available in a separate file for downloading).
Main clinical outcome measures
Main clinical outcome measures were prespecified and in-
clude stroke, systemic embolism, death, hospitalisation for
heart failure, myocardial infarction and bleeding. If a clin-
ical outcome measure is reported by the patient or detect-
ed in the medical records, detailed information is collected
from the corresponding hospitals and/or treating physi-
cians about this event. All main clinical outcome events
are adjudicated by a clinical event committee that is un-
aware of other study-specific information. The following
standardised definitions are used in Swiss-AF.
Stroke
Stroke is defined as an acute focal neurological deficit
of vascular origin, with evidence of focal infarction con-
firmed by imaging (computed tomography or cMRI) or au-
topsy. Stroke is categorised as ischaemic, haemorrhagic or
of unknown cause (based on computed tomography, cM-
RI, autopsy and other ancillary investigations). Ischaemic
strokes are further classified according to the TOAST clas-
sification [27]. Fatal stroke is defined as death from any
cause within 30 days after stroke.
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Systemic embolism
Systemic embolism is defined as acute vascular occlusion
of the extremities or any organ (kidneys, mesenteric arter-
ies, spleen, retina or grafts) and must be documented by
means of imaging, angiography, surgery or autopsy.
Mortality
The cause of death is classified as being of cardiac, stroke,
any cardiovascular, bleeding, non-cardiovascular or un-
known aetiology.
Major bleeding
Major bleeding is defined according to the International
Society on Thrombosis and Haemostasis criteria, as clin-
ically overt bleeding with a fatal outcome, a reduction in
haemoglobin level of ≥20 g/l within 7 days, transfusion
of at least two units of blood, or symptomatic bleeding in
a critical area or organ (intracranial, intraspinal, intraocu-
lar, pericardial, intra-articular, intramuscular with compart-
ment syndrome, retroperitoneal) [28].
Hospitalisation for congestive heart failure
Hospitalization for congestive heart failure is defined as
any unplanned hospitalisation for congestive heart failure
that is associated with at least one overnight stay.
Myocardial infarction
Myocardial infarction is defined as rise and/or fall of car-
diac troponin with at least one value above the 99th per-
centile of the upper reference limit in a clinical setting con-
sistent with myocardial ischaemia, and with at least one of
the following: symptoms of ischaemia, new significant ST-
T changes or new left bundle-branch block on ECG, devel-
opment of pathological Q waves in the ECG, imaging ev-
idence of new loss of viable myocardium or new regional
wall motion abnormality, identification of an intracoronary
thrombus by angiography or autopsy [29].
Drug adherence
Drug adherence is a key factor in the care of patients with
chronic diseases. Drug adherence in Swiss-AF is being as-
sessed using a validated adherence questionnaire (8-item
Morisky Medication Adherence Scale (MMAS-8)) [30].
Sample size and power
Clinical stroke
With 280 clinical stroke events expected and assuming a
β of 0.20 and an α of 0.05, the detectable stroke hazard
ratio is 1.5 for a binary predictor with a prevalence of
0.4. For binary predictors with a prevalence of 0.1, the de-
tectable stroke hazard ratio would be 1.9. Sensitivity analy-
ses shown in figs 3a and 3b demonstrate that the detectable
hazard ratio does not change substantially if the recruit-
ment is slightly lower than projected.
Silent cerebral infarction on magnetic resonance imag-
ing
For the cMRI endpoint of silent cerebral infarction (SCI),
we assume successful completion of two cMRI studies in
2160 patients (90% of the total sample without heart de-
vice), and an SCI incidence of 10% [13], such that 216 SCI
events are expected to occur. Assuming a β of 0.20 and an
α of 0.05, the detectable SCI hazard ratio will be 1.5 for a
binary predictor with a prevalence of 0.4. For a binary pre-
dictor with a prevalence of 0.1, the detectable SCI hazard
ratio would be 2.0. Again, a slightly lower recruitment rate
does only slightly change the detectable hazard ratios, as
shown in figs 4a and 4b.
Cognitive assessment
For the main cognitive assessment endpoint we will use
the MoCA total score. Assuming an enrolment of 2400 pa-
tients with a complete series of questionnaires and a stan-
dard deviation of 4 for the MoCA total score [31], a 1-point
difference on the MoCA score can be shown with >99%
power.
Figure 3a and 3b: Sample size calculation for clinical stroke.Sensitivity of the sample size with respect to stroke hazard ratio for a given
prevalence of 0.4 (a) or 0.1 (b). The vertical lines on the intersection point of the horizontal line and the power curves indicate how to read the
figures. The curve is smoothed for illustrative purposes.
Original article Swiss Med Wkly. 2017;147:w14467
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 9
Results
Up to 7 April 2017 the Swiss-AF study team has enrolled
2133 patients across 13 study centres into the cohort. Most
centres are hospital based, although specific efforts are be-
ing made to also recruit AF patients from general practi-
tioners. Recruitment rates are shown in figure 5. With the
current recruitment rate of 15–20 patients per week, we
expect that the recruitment target of 2400 patients will be
reached by summer 2017.
Discussion
Swiss-AF is a large, multicentre prospective cohort study
of mainly elderly patients with AF. This project will estab-
lish a large interdisciplinary platform to study the interre-
lationships of AF and AF progression with structural and
functional brain damage over time.
We expect that several important findings will emerge
from Swiss-AF. Although the increased risk of cognitive
dysfunction and dementia among patients with AF is well
described [9–12], its underlying mechanisms are not well
understood. Not surprisingly, one meta-analysis suggested
that the relative risk of incident dementia is higher among
individuals with a history of clinical stroke [11], but also
Figure 5: Swiss-AF patient recruitment up to 7 April 2016, strati-
fied by AF type.AF = atrial fibrillation
remained significantly increased among AF patients with-
out a history of stroke. Our study will offer opportunities to
investigate whether the residual risk is due to silent, clini-
cally not recognisable strokes or other structural brain ab-
normalities such as white matter lesions, microinfarctions
or microbleeds. It will be particularly important to assess
the effect of microbleeds, given the clear indication for oral
anticoagulation for most patients with AF. Further, we will
also assess in detail the influence of known cardiovascular
risk factors such as obesity and hypertension on structural
and function brain parameters [32, 33].
In addition, this long term study will shed light on the im-
pact of AF progression over time on quality of life, symp-
toms and various cardiovascular and non-cardiovascular
outcomes among patients with non-permanent AF [5, 34].
Detailed cost and quality of life-related analyses will pro-
vide key information on the quality and cost of AF-related
medical resource use in Switzerland, and provide a basis
for the health economic evaluation of alternative treatment
strategies. Disability, drug adherence and quality of life are
important patient related metrics that will help to better in-
form patients with AF. Finally, the study also aims to im-
prove understanding of underlying AF-related mechanisms
and detailed genetic analyses will be a particular focus of
this project.
In addition to its many strengths, there are some potential
limitations of this project. First, it is important to empha-
sise that Swiss-AF does not have a control group of pa-
tients without AF. However, extensive resources of other
cohort studies in Switzerland and internationally are avail-
able for comparison, and through discussions with respec-
tive study leaders we tried to harmonise study definitions
and recording protocols as much as possible. Second, cM-
RI is without the application of intravenous contrast
agents. This decision was made because the application of
gadolinium contrast agents has been associated with rare
but significant risks, would have significantly increased
the study costs and the burden for the patient, and the main
parameters to be studied in Swiss-AF (stroke, microbleeds,
Figure 4a and 4b: Sample size calculation for silent cerebral infarctions.Sensitivity of the sample size with respect to the silent cerebral infarc-
tion hazard ratio for a given prevalence of 0.4 (a) or 0.1 (b). The vertical lines on the intersection point of the horizontal line and the power
curves indicate how to read the figures. The curve is smoothed and for illustrative purposes.
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microangiopathy) do not need the application of MRI con-
trast.
In conclusion, Swiss-AF is a large national prospective co-
hort of patients with AF in Switzerland. This study will
provide pertinent new information on structural and func-
tional brain damage in patients with AF and on other AF
related complications, using a large variety of genetic, phe-
notypic and health economic parameters.
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Appendix 1: Swiss-AF study investigators (in
addition to all co-authors)
University Hospital Basel/Basel University: Stefanie
Aeschbacher, Steffen Blum, Fatih Metin, Laura Doerig,
Matylda Zimny, Anna Maseli, Lucien Eggimann, Peter
Egli, Andreas Fischer, Thomas Kofler, Rahel Kreuzmann,
Philipp Krisai, Pascal Meyre, Christoph Muff, Christiane
Pudenz, Andreas Reusser, Javier Ruperti Repilado, Alek-
sandra Schweizer, Anne Springer, Thomas Szucs,
Stephanie van der Lely, Jan van der Stouwe, Gian
Voellmin, Mirco von Rotz.
University Hospital Bern: Faculty: Drahomir Aujesky,
Juerg Fuhrer, Simon Jung, Heinrich Mattle; Research fel-
lows: Luise Adam, Carole Elodie Aubert, Martin Feller,
Regula Kronenberg, Elisavet Moutzouri, Claudio Schnei-
der, Daniel Segna; Study nurses: Evelyne Abgottspon,
Tanja Flückiger, Cindy Groen, Svenja Heger, Sarah Pfaf-
fen.
Stadtspital Triemli Zurich: Christopher Beynon, Roger
Dillier, Franz Eberli, Simone Fontana, Christine Franzini,
Isabel Juchli, Claudia Liedtke, Jacqueline Nadler, Thayze
Obst, Xiaoye Schneider, Katrin Studerus, Dominik
Weishaupt.
Kantonspital Baden: Silke Kuest, Karin Scheuch, Denise
Hischier, Nicole Bonetti, Corina Bello, Henriette Isberg,
Alexandra Grau, Jonas Villinger, Mary-Monica Papaux.
Cardiocentro Lugano: Adriana Anesini, Cristina Campori-
ni, Giulio Conte, Tiziano Moccetti.
Kantonsspital St. Gallen: Roman Brenner, Manuela Forrer,
Michaela Gemperle.
Hôpital Cantonal Fribourg: Mathieu Firmann, Sandrine
Foucras.
Luzerner Kantonsspital: Benjamin Berte, Andrea Kaep-
peli, Brigitta Mehmann, Markus Pfeiffer, Ian Russi, Kai
Schmidt, Vanessa Weberndoerfer, Mabelle Young, Melanie
Zbinden
EOC Lugano: Lorenzo Baldecchi, Jane Frangi, Tatiana
Terrot.
University Hospital Geneva: Hervé Gallet, Elise Guiller-
met, Francois Lazeyras, Karl-Olof Lovblad, Patrick Perret,
Cheryl Teres.
University Hospital Lausanne: Nathalie Lauriers, Marie
Mean Pascual, Sandrine Salzmann.
Bürgerspital Solothurn: Nisha Arenja, Andrea Grêt, Sandra
Vitelli.
EOC Bellinzona: Jane Frangi, Augusto Gallino.
St. Anna Spital Luzern: Renate Schoenenberger-Berzins.
University of Zurich: Fabienne Witassek.
Medical Image Analysis Center AG Basel: Ernst-Wilhelm
Radue, Tim Sinnecker.
Clinical Trial Unit Basel: Pascal Benkert, Thomas Fabbro,
Patrick Simon
Schiller AG Baar: Ramun Schmid.
Appendix 2: Employment questionnaire for
patients aged <65 years
The questionnaire is available as a separate file at:
https://smw.ch/en/article/doi/smw.2017.14467/
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